Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell ca...

by Machiels, Jean-Pascal H, Licitra, Lisa F, Haddad, Robert I, Tahara, Makoto, Cohen, Ezra EW
Published 2014

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

by Ercolini, Anne M., Ladle, Brian H., Manning, Elizabeth A., Pfannenstiel, Lukas W., Armstrong, Todd D., Machiels, Jean-Pascal H., Bieler, Joan G., Emens, Leisha A., Reilly, R. Todd, Jaffee, Elizabeth M.
Published 2005

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metast...

by Lonez, Caroline, Verma, Bikash, Hendlisz, Alain, Aftimos, Philippe, Awada, Ahmad, Van Den Neste, Eric, Catala, Gaetan, Machiels, Jean-Pascal H, Piette, Fanny, Brayer, Jason B, Sallman, David A, Kerre, Tessa, Odunsi, Kunle, Davila, Marco L, Gilham, David E, Lehmann, Frédéric F
Published in BMJ Open (2017)

Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies

by Springuel, Lorraine, Lonez, Caroline, Alexandre, Bertrand, Van Cutsem, Eric, Machiels, Jean-Pascal H., Van Den Eynde, Marc, Prenen, Hans, Hendlisz, Alain, Shaza, Leila, Carrasco, Javier, Canon, Jean-Luc, Opyrchal, Mateusz, Odunsi, Kunle, Rottey, Sylvie, Gilham, David E., Flament, Anne, Lehmann, Frédéric F.
Published in BioDrugs (2019)

EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients

by Hu-Lieskovan, Siwen, Vallbohmer, Daniel, Zhang, Wu, Yang, Dongyun, Pohl, Alexander, Labonte, Melissa, Grimminger, Peter P., Hölscher, Arnulf H., Semrau, Robert, Arnold, Dirk, Dellas, Kathrin, Debucquoy, Annelies, Haustermans, Karin, Machiels, Jean-Pascal H., Sempoux, Christine, Rödel, Claus, Bracko, Matej, Velenik, Vaneja, Lenz, Heinz-Josef
Published 2011

A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors

by de Braud, Filippo, Machiels, Jean-Pascal H., Boggiani, Daniela, Rottey, Sylvie W.H., Duca, Matteo, Laruelle, Marie, Salvagni, Stefania, Damian, Silvia, Lapeire, Lore D.F., Tiseo, Marcello, Dermine, Alexandre, Ould-Kaci, Mahmoud, Braunger, Juergen, Rascher, Juliane, Fischer, Daniela, Hoefler, Josef, Mariani, Gabriella L., Cresta, Sara
Published in Cancers (Basel) (2020)

Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040

by Harrington, Kevin J, Soulières, Denis, Le Tourneau, Christophe, Dinis, Jose, Licitra, Lisa F, Ahn, Myung-Ju, Soria, Ainara, Machiels, Jean-Pascal H, Mach, Nicolas, Mehra, Ranee, Burtness, Barbara, Ellison, Misoo C, Cheng, Jonathan D, Chirovsky, Diana Romana, Swaby, Ramona F, Cohen, Ezra E W
Published in J Natl Cancer Inst (2020)